Proactive Investors
23 Oct 2026, 13:48 UTC · 1h ago
Oxford BioMedica's AI tools could cut development time by 80%, Jefferies says
Impact · against what's priced in
Oxford BioMedica is positioned for a valuation re-rating based on significant efficiency gains from AI-driven development and a robust $713 million pipeline. While recent guidance revisions created uncertainty, the combination of a £168 million revenue floor and high proposal conversion rates provides a strong catalyst for upside.
- OXB+0.70
No priced-in read yet
- In context
The use of automated Design of Experiments to cut development time by 80% and a 30% increase in the new-business pipeline to $713 million provide concrete growth catalysts.
Read from the article alone
